Active surveillance ‘safe and effective’ for low-risk prostate cancer
At 10 years post-diagnosis, fewer than 2% of patients developed metastatic disease.
Active surveillance is an effective management strategy for men with favourable-risk prostate cancer, with an estimated rate of metastasis of 1.4% at 10 years after diagnosis, according to a study in the Journal of the American Medical Association.
Dr Lisa Newcomb (PhD), from the Fred Hutchinson Cancer Center in Seattle in the US, and colleagues characterised the long-term oncological outcomes of patients receiving active surveillance, in a multicentre cohort study.
